National Institute of Allergy and Infectious Diseases (NIAID), U.S. National Institutes of Health (NIH), Bethesda, MD 20892, USA.
Sci Transl Med. 2011 Nov 2;3(107):107fs7. doi: 10.1126/scitranslmed.3002878.
Participants at the February 2011 meeting at the U.S. National Institutes of Health on Epstein-Barr virus (EBV) vaccine research recommend that future clinical trials have two goals: prevention of infectious mononucleosis and EBV-associated cancers, facilitated by identification of disease-predictive surrogate markers.
与会者在 2011 年 2 月美国国立卫生研究院召开的关于爱泼斯坦-巴尔病毒（EBV）疫苗研究的会议上建议，未来的临床试验应具有两个目标：通过识别疾病预测替代标志物，预防传染性单核细胞增多症和 EBV 相关癌症。
